Design and implementation of a soft-decision decoder for Cortex codes

International audienceCortex codes are a family of rate-1/2 self-dual systematic linear block codes with good distance properties. This paper investigates the challenging issue of designing an efficient soft-decision decoder for Cortex codes. A dedicated algorithm is introduced that takes advantage of the particular structure of the code to simplify the decoding. Simulation results show that the proposed algorithm achieves an excellent trade-off between performance and complexity for short Cortex codes. A decoder architecture for the (32,16,8) Cortex code based on the (4,2,2) Hadamard code has been successfully designed and implemented on FPGA device. To our knowledge, this is the first efficient digital implementation of a soft-decision Cortex decoder

COVID-19 symptoms at hospital admission vary with age and sex: results from the ISARIC prospective multinational observational study

Background: The ISARIC prospective multinational observational study is the largest cohort of hospitalized patients with COVID-19. We present relationships of age, sex, and nationality to presenting symptoms. Methods: International, prospective observational study of 60 109 hospitalized symptomatic patients with laboratory-confirmed COVID-19 recruited from 43 countries between 30 January and 3 August 2020. Logistic regression was performed to evaluate relationships of age and sex to published COVID-19 case definitions and the most commonly reported symptoms. Results: ‘Typical’ symptoms of fever (69%), cough (68%) and shortness of breath (66%) were the most commonly reported. 92% of patients experienced at least one of these. Prevalence of typical symptoms was greatest in 30- to 60-year-olds (respectively 80, 79, 69%; at least one 95%). They were reported less frequently in children (≤ 18 years: 69, 48, 23; 85%), older adults (≥ 70 years: 61, 62, 65; 90%), and women (66, 66, 64; 90%; vs. men 71, 70, 67; 93%, each P < 0.001). The most common atypical presentations under 60 years of age were nausea and vomiting and abdominal pain, and over 60 years was confusion. Regression models showed significant differences in symptoms with sex, age and country. Interpretation: This international collaboration has allowed us to report reliable symptom data from the largest cohort of patients admitted to hospital with COVID-19. Adults over 60 and children admitted to hospital with COVID-19 are less likely to present with typical symptoms. Nausea and vomiting are common atypical presentations under 30 years. Confusion is a frequent atypical presentation of COVID-19 in adults over 60 years. Women are less likely to experience typical symptoms than men

Procédé de codage de données à au moins deux étapes d'encodage à et au moins une étape de permutation, dispositif de codage, programme d'ordinateur et signal correspondants

l'invention concerne un procédé de codage de données destinées à être transmises vers au moins un récepteur, comprenant au moins deux étapes d'encodages identiques et au moins une étape de permutation, chaque étape d'encodage associant à un bloc de données à coder un bloc de données codées, à l'aide d'au moins deux codes de base, traitant chacun un sous-ensemble dudit bloc de données à coder, et une étape de permutation étant intercalée entre deux étapes d'encodage, une étape d'encodage courante et une étape d'encodage précédente, de facon que l'ordre des données d'un bloc de données à coder par ladite étape d'encodage courante soit différent de l'ordre de ces données codées par ladite étape d'encodage précédente. Selon l'invention, ladite étape de permutation met en oeuvre, pour un bloc de données, une rotatin appliquée aux données dudit bloc de données et une inversion de l'ordre des données dudit bloc de données. Ces opérations peuvent être mises en oeuvre à l'aide d'une matrice d'entrelacement

A subthreshold PMOS analog cortex decoder for the (8,4,4) hamming code

International audienceThis paper presents a method for decoding high minimal distances (dmin) short codes termed Cortex codes. These codes are systematic block codes of rate 1/2 and can have higher dmin than turbo codes. Despite this characteristic, these codes were impossible to decode with good performance. This is due to the fact that to reach high dmin, several encoding stages are connected through interleavers. This generates a large number of hidden variables and complexifies the scheduling and the initialization. However, the structure of the encoder is well suited for analog decoding. A proof-of-concept Cortex decoder for the (8,4,4) Hamming code has been implemented in subthreshold 0.25-µm CMOS. It outperforms an equivalent LDPC-like decoder by 1dB at BER=10E-5 while being 44 percent smaller and consuming 28 percent less energy per decoded bi

Decoding a family of dense codes using the sum-product algorithm and subthreshold PMOS

International audienceCortex codes are a family of block codes with goodminimum distance properties whose parity-check matrices are very dense. Digital implementations of Cortex decoders using standard decoding algorithms have not shown an acceptable performance. Motivated by the encoder structure, a new bipartite graph is introduced and exemplified for the Cortex construction of the extended Hamming code. The Cortex graph has longer girth and approximately 80% less cycles than the Tanner graph. A Cortex and an LDPC-like decoder were implemented for the same code using identical PMOS-based Gilbert multipliers. This makes them the first reported analog decoders using mainly PMOS transistors. The Cortex outperforms the LDPC-like decoder in Bit Error Rate and at the same time saves 44% of die surface. The results are supported using data from a test chip designed for a 0.25 um CMOS process

Cortex codes and analogue decoding

International audience

Scaling of analog LDPC decoders in sub-100nm CMOS processes

International audienceAnalog implementations of digital error control decoders, generally referred to as analog decoding, have recently been proposed asan energy and area competitive methodology. Despite several successful implementations of small analog error control decoders, little is currently known about how this methodology scales to smaller process technologies and copes with the non-idealities of nano-scale transistor sizing. A comprehensive analysis of the potential of sub-threshold analog decoding is examined in this paper. It is shown that mismatch effects dominated by threshold mismatch impose firm lower limits on the sizes of transistors. The effect of various forms of leakage currents is also investigated and minimal leakage current to normalizing currents are found using density evolution and control simulations. Finally, the convergence speed of analog decoders is examined via a density evolution approach. The results are compiled and predictions are given which show that process scaling below 90nm processes brings no advantages, and, in some cases, may even degrade performance or increase required resources

Paediatric COVID-19 mortality: a database analysis of the impact of health resource disparity

Background The impact of the COVID-19 pandemic on paediatric populations varied between high-income countries (HICs) versus low-income to middle-income countries (LMICs). We sought to investigate differences in paediatric clinical outcomes and identify factors contributing to disparity between countries.Methods The International Severe Acute Respiratory and Emerging Infections Consortium (ISARIC) COVID-19 database was queried to include children under 19 years of age admitted to hospital from January 2020 to April 2021 with suspected or confirmed COVID-19 diagnosis. Univariate and multivariable analysis of contributing factors for mortality were assessed by country group (HICs vs LMICs) as defined by the World Bank criteria.Results A total of 12 860 children (3819 from 21 HICs and 9041 from 15 LMICs) participated in this study. Of these, 8961 were laboratory-confirmed and 3899 suspected COVID-19 cases. About 52% of LMICs children were black, and more than 40% were infants and adolescent. Overall in-hospital mortality rate (95% CI) was 3.3% [=(3.0% to 3.6%), higher in LMICs than HICs (4.0% (3.6% to 4.4%) and 1.7% (1.3% to 2.1%), respectively). There were significant differences between country income groups in intervention profile, with higher use of antibiotics, antivirals, corticosteroids, prone positioning, high flow nasal cannula, non-invasive and invasive mechanical ventilation in HICs. Out of the 439 mechanically ventilated children, mortality occurred in 106 (24.1%) subjects, which was higher in LMICs than HICs (89 (43.6%) vs 17 (7.2%) respectively). Pre-existing infectious comorbidities (tuberculosis and HIV) and some complications (bacterial pneumonia, acute respiratory distress syndrome and myocarditis) were significantly higher in LMICs compared with HICs. On multivariable analysis, LMIC as country income group was associated with increased risk of mortality (adjusted HR 4.73 (3.16 to 7.10)).Conclusion Mortality and morbidities were higher in LMICs than HICs, and it may be attributable to differences in patient demographics, complications and access to supportive and treatment modalities

Respiratory support in patients with severe COVID-19 in the International Severe Acute Respiratory and Emerging Infection (ISARIC) COVID-19 study: a prospective, multinational, observational study

Background: Up to 30% of hospitalised patients with COVID-19 require advanced respiratory support, including high-flow nasal cannulas (HFNC), non-invasive mechanical ventilation (NIV), or invasive mechanical ventilation (IMV). We aimed to describe the clinical characteristics, outcomes and risk factors for failing non-invasive respiratory support in patients treated with severe COVID-19 during the first two years of the pandemic in high-income countries (HICs) and low middle-income countries (LMICs). Methods: This is a multinational, multicentre, prospective cohort study embedded in the ISARIC-WHO COVID-19 Clinical Characterisation Protocol. Patients with laboratory-confirmed SARS-CoV-2 infection who required hospital admission were recruited prospectively. Patients treated with HFNC, NIV, or IMV within the first 24 h of hospital admission were included in this study. Descriptive statistics, random forest, and logistic regression analyses were used to describe clinical characteristics and compare clinical outcomes among patients treated with the different types of advanced respiratory support. Results: A total of 66,565 patients were included in this study. Overall, 82.6% of patients were treated in HIC, and 40.6% were admitted to the hospital during the first pandemic wave. During the first 24 h after hospital admission, patients in HICs were more frequently treated with HFNC (48.0%), followed by NIV (38.6%) and IMV (13.4%). In contrast, patients admitted in lower- and middle-income countries (LMICs) were less frequently treated with HFNC (16.1%) and the majority received IMV (59.1%). The failure rate of non-invasive respiratory support (i.e. HFNC or NIV) was 15.5%, of which 71.2% were from HIC and 28.8% from LMIC. The variables most strongly associated with non-invasive ventilation failure, defined as progression to IMV, were high leukocyte counts at hospital admission (OR [95%CI]; 5.86 [4.83-7.10]), treatment in an LMIC (OR [95%CI]; 2.04 [1.97-2.11]), and tachypnoea at hospital admission (OR [95%CI]; 1.16 [1.14-1.18]). Patients who failed HFNC/NIV had a higher 28-day fatality ratio (OR [95%CI]; 1.27 [1.25-1.30]). Conclusions: In the present international cohort, the most frequently used advanced respiratory support was the HFNC. However, IMV was used more often in LMIC. Higher leucocyte count, tachypnoea, and treatment in LMIC were risk factors for HFNC/NIV failure. HFNC/NIV failure was related to worse clinical outcomes, such as 28-day mortality. Trial registration This is a prospective observational study; therefore, no health care interventions were applied to participants, and trial registration is not applicable

Respiratory support in patients with severe COVID-19 in the International Severe Acute Respiratory and Emerging Infection (ISARIC) COVID-19 study: a prospective, multinational, observational study

Background: Up to 30% of hospitalised patients with COVID-19 require advanced respiratory support, including high-flow nasal cannulas (HFNC), non-invasive mechanical ventilation (NIV), or invasive mechanical ventilation (IMV). We aimed to describe the clinical characteristics, outcomes and risk factors for failing non-invasive respiratory support in patients treated with severe COVID-19 during the first two years of the pandemic in high-income countries (HICs) and low middle-income countries (LMICs). Methods: This is a multinational, multicentre, prospective cohort study embedded in the ISARIC-WHO COVID-19 Clinical Characterisation Protocol. Patients with laboratory-confirmed SARS-CoV-2 infection who required hospital admission were recruited prospectively. Patients treated with HFNC, NIV, or IMV within the first 24 h of hospital admission were included in this study. Descriptive statistics, random forest, and logistic regression analyses were used to describe clinical characteristics and compare clinical outcomes among patients treated with the different types of advanced respiratory support. Results: A total of 66,565 patients were included in this study. Overall, 82.6% of patients were treated in HIC, and 40.6% were admitted to the hospital during the first pandemic wave. During the first 24 h after hospital admission, patients in HICs were more frequently treated with HFNC (48.0%), followed by NIV (38.6%) and IMV (13.4%). In contrast, patients admitted in lower- and middle-income countries (LMICs) were less frequently treated with HFNC (16.1%) and the majority received IMV (59.1%). The failure rate of non-invasive respiratory support (i.e. HFNC or NIV) was 15.5%, of which 71.2% were from HIC and 28.8% from LMIC. The variables most strongly associated with non-invasive ventilation failure, defined as progression to IMV, were high leukocyte counts at hospital admission (OR [95%CI]; 5.86 [4.83–7.10]), treatment in an LMIC (OR [95%CI]; 2.04 [1.97–2.11]), and tachypnoea at hospital admission (OR [95%CI]; 1.16 [1.14–1.18]). Patients who failed HFNC/NIV had a higher 28-day fatality ratio (OR [95%CI]; 1.27 [1.25–1.30]). Conclusions: In the present international cohort, the most frequently used advanced respiratory support was the HFNC. However, IMV was used more often in LMIC. Higher leucocyte count, tachypnoea, and treatment in LMIC were risk factors for HFNC/NIV failure. HFNC/NIV failure was related to worse clinical outcomes, such as 28-day mortality. Trial registration This is a prospective observational study; therefore, no health care interventions were applied to participants, and trial registration is not applicable